Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Post Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteriovenous Fistulae
NCT03506308 · View on ClinicalTrials.gov ↗
Study Summary
This prospective, global, multicenter, single arm post-approval study is designed to investigate the clinical use and safety of the Lutonix® 035 AV Drug Coated Balloon (DCB) PTA Catheter in subjects presenting with clinical and hemodynamic abnormalities in native arteriovenous (AV) fistulae located in the upper extremity.
Conditions Studied
Interventions
- DEVICE LUTONIX 035 Drug Coated Balloon PTA Catheter
Study Locations (20)
Texas
- Dallas Vascular Center — Dallas
- HCA Houston Healthcare — Houston
- Houston Methodist Hospital — Houston
Alabama
- University of Alabama at Birmingham — Birmingham
- Flowers Hospital — Dothan
California
- St. Joseph Hospital of Orange — Orange
- Kaiser Permanente — San Diego
Louisiana
- Ochsner Health System — New Orleans
- Ochsner Louisiana State University Health — Shreveport
New York
- Columbia University Medical Center — New York
- Rochester General Hospital — Rochester
Connecticut
- Yale University — New Haven
Iowa
- University of Iowa Hospital and Clinics — Iowa City
Kentucky
- University of Louisville — Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2018-08-07 |
| Est. Completion | 2030-04 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03506308
The ClinicalTrials.gov registry entry for NCT03506308 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C. R. Bard, which has 46 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Arteriovenous Fistula appearing as the primary indexed condition, and to 1 intervention — of which LUTONIX 035 Drug Coated Balloon PTA Catheter is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03506308 reports 20 study locations spanning 14 distinct geographic areas — top geographies include Texas, Alabama, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03506308 about?
NCT03506308 is a clinical study titled "Post Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteriovenous Fistulae". This prospective, global, multicenter, single arm post-approval study is designed to investigate the clinical use and safety of the Lutonix® 035 AV Drug Coated Balloon (DCB) PTA Catheter in subjects presenting with clinical and hemodynamic abnormalities in native arteriovenous (AV) fistulae located ...
What is the current status of trial NCT03506308?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 213 participants. The study started on 2018-08-07. Estimated completion is 2030-04.
What conditions does trial NCT03506308 study?
This clinical trial studies the following conditions: Arteriovenous Fistula. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03506308?
The interventions under investigation include: LUTONIX 035 Drug Coated Balloon PTA Catheter (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03506308?
This trial is sponsored by C. R. Bard, which has 46 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03506308 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Iowa, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.